According to the 2025 “National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue” published by the National Health Insurance Administration, two domestically produced anti-influenza virus drugs that were newly approved for marketing this year successfully entered the catalogue, namely Onradivir tablets from Zhongsheng Pharmaceutical and masulasavir tablets from Qingfeng Pharmaceutical.

Zhitongcaijing · 2d ago
According to the 2025 “National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue” published by the National Health Insurance Administration, two domestically produced anti-influenza virus drugs that were newly approved for marketing this year successfully entered the catalogue, namely Onradivir tablets from Zhongsheng Pharmaceutical and masulasavir tablets from Qingfeng Pharmaceutical.